ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy
暂无分享,去创建一个
G. Bodoky | J. Douillard | A. Awada | M. Di Nicola | J. Pérez-Gracia | H. Arkenau | T. Amaral | M. Lolkema | N. Penel | M. Sanmamed | V. Gruenwald | R. Vera | E. Calvo
[1] F. Ciardiello,et al. Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer , 2019, ESMO Open.
[2] S. Rule,et al. Bureaucracy is strangling clinical research , 2019, BMJ.
[3] D. Galetta,et al. Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer , 2017, Clinical lung cancer.
[4] Edward S. Kim,et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Caroline Schenkel,et al. Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Richard Pazdur,et al. Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Xian-Jin Xie,et al. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] D. Lacombe,et al. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients , 2017, ESMO Open.
[9] R. Labianca,et al. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] C. Dooms,et al. The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database. , 2016, Lung cancer.
[11] F. Shepherd,et al. Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] C. Dooms,et al. Lung cancer at the intensive care unit: The era of targeted therapy. , 2015, Lung cancer.
[13] H. Kantarjian,et al. Impact of cancer research bureaucracy on innovation, costs, and patient care. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Domján Andrea,et al. World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects , 2014 .